

Meet The Professor: Optimizing the Selection and Sequencing of Therapy for Patients with Renal Cell Carcinoma**THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. Which of the following drugs is being evaluated in the Phase III CONTACT-03 trial in combination with cabozantinib versus cabozantinib alone for patients with advanced renal cell carcinoma (RCC) who previously received immunotherapy?**
 - a. Pembrolizumab
 - b. Nivolumab
 - c. Atezolizumab**
- 2. In the randomized Phase III TIVO-3 trial comparing tivozanib to sorafenib for patients with metastatic RCC after failure of 2 or 3 prior systemic regimens, including a VEGFR tyrosine kinase inhibitor other than sorafenib or tivozanib, which of the following results was reported?**
 - a. A statistically significant improvement in progression-free survival (PFS) but not overall survival (OS) with tivozanib**
 - b. A statistically significant improvement in OS but not PFS with tivozanib
 - c. A statistically significant improvement in both PFS and OS with tivozanib
- 3. On the basis of results from the Phase III CheckMate 214 trial, the combination of nivolumab and ipilimumab received FDA approval for patients with intermediate- or poor-risk advanced RCC in which line of treatment?**
 - a. First line**
 - b. Second line after sunitinib
 - c. Third line or later
- 4. Which of the following drug types best describes the mechanism of action of the novel agent belzutifan?**
 - a. VEGF inhibitor
 - b. HIF-2 inhibitor**
 - c. mTOR inhibitor